What is Bionyra Pharma?
Bionyra Pharma operates as a clinical-stage biotechnology enterprise dedicated to the advancement of next-generation biologic therapies. The company specializes in the development of monoclonal and multispecific antibody programs designed to modulate key immune pathways associated with severe immune-mediated inflammatory diseases. By leveraging innovative antibody engineering, Bionyra Pharma aims to provide superior therapeutic outcomes for patients diagnosed with conditions such as inflammatory bowel disease and atopic dermatitis. The company's market position is defined by its focus on precision medicine and its ability to translate complex scientific research into viable clinical candidates that offer deeper disease control compared to existing standards of care.
How much funding has Bionyra Pharma raised?
Bionyra Pharma has raised a total of $165M across 1 funding round:
Series A
$165M
Series A (2026): $165M with participation from Sofinnova Partners, Vives, Arkin Holdings, Sanofi Ventures, Sixty Degree Capital, Jeito, and Apollo Health Ventures
Key Investors in Bionyra Pharma
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
Vives
VIVES is a multi-sector investment fund initiated by UCLouvain that focuses on supporting and strengthening innovative business projects with a positive societal impact.
Arkin Holdings
Arkin Capital is a prominent multi-asset manager that excels in making strategic investments through specialized arms, including Arkin Health for healthcare innovations.
What's next for Bionyra Pharma?
With the successful closure of this major enterprise-level funding, Bionyra Pharma is poised to scale its clinical operations significantly. The strategic roadmap for the coming quarters involves the advancement of its lead candidates through critical clinical trial milestones, ensuring that the company remains at the forefront of immunology research. Furthermore, the firm intends to utilize this capital to expand its internal research capabilities and strengthen its intellectual property portfolio. As the company moves forward, the focus will remain on optimizing its antibody engineering platform to potentially address a broader spectrum of inflammatory disorders, thereby solidifying its role as a key player in the global biotechnology landscape.
See full Bionyra Pharma company page
